Ferlito A, Barnes L, Rinaldo A, et al
In addition, similar to other GLP-1 RAs, it affects different stages of the pathophysiological process of CVDs, from risk factors like dyslipidemia, hypertension, obesity, diabetes, and coronary artery atherosclerosis to more advanced stages such as myocardial ischemia, atherothrombosis, myocardial infarction, left ventricular remodeling, and death, without raising the risk of arrhythmia, hospitalization, or exacerbating heart failure [35, 41]
131,225 GLP-1s action on -cells regulates glucagon release
Other positive CV outcome trials for SGLT-2 inhibitors followed, 8,9 and in a meta-analysis the class clearly shows a significant 10% reduction of major CV events related to atherosclerotic CV disease, which has informed the changes to the PBS
Raven et al184 underscored the importance of considering the interactions between GLP-1RAs therapy, comorbid conditions, and concomitant medications that may also delay gastric emptying
Maintenance drops to 2mg weekly or less frequently
